Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Autism Spectrum Disorders (ASD) comprises a complex group of disorders of neuronal development characterized by social and communication impairment along with presence of repetitive and restrictive behaviors. Emerging evidences support the gut-brain axis and further microbiota-gut-brain axis. Elevated prevalence of gastrointestinal (GI) dysfunction in individuals with ASD suggested that targeting gut may benefit patients with ASD. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal studies which modulated the levels of neurotransmitters in different brain areas. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in preschool children with ASD.
Emerging evidences support the gut-brain axis and further microbiota-gut-brain axis. Elevated prevalence of gastrointestinal (GI) dysfunction in individuals with ASD suggested that targeting gut may benefit patients with ASD. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal studies which modulated the levels of neurotransmitters in different brain areas. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in preschool children with ASD.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lactobacillus plantarum PS128 (PS128) | Active Comparator | Subjects will receive oral Lactobacillus plantarum PS128 capsules, 2 capsules per day, for 16 weeks. |
|
| Placebo | Placebo Comparator | Subjects will receive oral placebo capsules, 2 capsules per day, for the first 8 weeks. The following 8 weeks, subjects will receive oral Lactobacillus plantarum PS128 capsules, 2 capsules per day, for 8 weeks. |
|
| Normal Control | No Intervention | Normal control group are enrolled by invitation from the age and gender matched healthy children. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Probiotic, Lactobacillus plantarum PS128 | Other | PS128 capsules, 2 capsules per day |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes from baseline of anxiety subscale in Children's Behavior Checklist (CBCL)/Achenbach System of Empirically Based Assessment (ASEBA) at week 8 and week 16 | ASEBA for behavioral assessment | Baseline, week 8 and week 16 |
| Changes from hyperactivity subscale of Attention-Deficit/Hyperactivity Disorder Test (ADHDT) at week 8 and week 16 | Inattention, hyperactive symptoms evaluation | Baseline, week 8 and week 16 |
| Measure | Description | Time Frame |
|---|---|---|
| Gastrointestinal symptoms recorded by using GI Severity Index (6-GSI) at week 8 and week 16 | constipation, diarrhea, stool consistency, stool smell, flatulence, and abdominal pain | Baseline, week 8 and week 16 |
| Change of total scores at week 8 and week 16 from baseline of Changes of Childhood Asperger Syndrome Test (CAST) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hui-Ju Chen MD | Contact | 02-25433535 | hjuchen0623@gmail.com | |
| Hui-Ju Chen MD | Contact | 02-25433535 | mmhcto@gmail.com; a6284@mmh.org.tw |
| Name | Affiliation | Role |
|---|---|---|
| Hui-Ju Chen MD | Department of Pediatric Neurology, MacKay Children's Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Pediatric Neurology, MacKay Children's Hospital | Recruiting | Taipei | Taiwan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001321 | Autistic Disorder |
| ID | Term |
|---|---|
| D000067877 | Autism Spectrum Disorder |
| D002659 | Child Development Disorders, Pervasive |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D019936 | Probiotics |
| C109691 | microcrystalline cellulose |
| ID | Term |
|---|---|
| D019587 | Dietary Supplements |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
Not provided
Not provided
Double-blinded, randomized, placebo-controlled
Not provided
Not provided
Investigators, researchers, outcome assessors, subjects and caregivers will be blinded to the randomization. A research assistant who is not involved in this trial will do the randomization by using randomly permuted blocks within the strata of two assignments, the placebo group and PS128 group with the ratio of 1:1.
| Placebo, microcrystalline cellulose | Other | Placebo capsules, 2 capsules per day |
|
|
CAST for behavioral assessment |
| Baseline, week 8 and week 16 |
| Change of total scores at week 8 and week 16 from baseline of Penn Interactive Peer Play Scale, (PIPPS) | PIPPS for communicative and interactive assessment | Baseline, week 8 and week 16 |
| Change of total scores at week 8 and week 16 from baseline of Social Interaction Assessment Scale | Communicative and interactive assessment | Baseline, week 8 and week 16 |
| Comparison of Microbiota composition between week 8 and baseline | Gut and oral microbiota analysis | Baseline and week 8 |
| D019602 |
| Food and Beverages |